PARADIGM BIOPHARMACEUTICALS LIMITED

ASX RELEASE 6th January 2021

PARADIGM BIOPHARMACEUTICALS TO PRESENT AT THE 39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is pleased to announce it will be presenting at the upcoming 39th Annual J.P. Morgan Healthcare Conference. Public listeners will have an opportunity to listen to the live audio (non-video) version of the session via the link provided below. A replay of the webcast will be available shortly after the conclusion of the presentation and will be available on Paradigm's website following the presentation. Paradigm's management will also be participating in several meetings throughout the conference with pharmaceutical companies and specialist US Biotech and Healthcare funds, where the company will be detailing its Phase 3 clinical program for Zilosul® and discussing other exciting indications in the company's clinical pipeline.

Presentation Details:

Event: 39th Annual J.P. Morgan Healthcare Conference

Time: AUS: Wednesday 13th January, 8:20am (AEDT)

US: Tuesday 12th January, 4:20pm (Eastern)

Link: https://jpmorgan.metameetings.net/events/healthcare21/sessions/35263-paradigm-biopharmaceuticals-ltd/webcast?gpu_only=true&kiosk=true

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulphate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition.

Authorised for release by Paul Rennie, CEO & Interim Executive Chairman.

To learn more about Paradigm Biopharmaceuticals please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com